Anna Melissa Lo, MD
Endocrinology, Diabetes & Metabolism · Honolulu, HINPI 1417308685
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.6% of the total across 602 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 29 manufacturers, the largest accounting for just 13.8% — the pattern of someone who eats at a lot of different presentations.
Across 602 payments — averaging $21.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$2K
- Novo Nordisk$2K
- Lilly USA, LLC$2K
- Dexcom, Inc.$1K
- Bayer$1K
- Abbott$1K
- plus $5K from 23 others
What the payments were for
- Food & beverage$12,85799%
- Education$701%
- Gifts$1191%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 87 | $1,803 |
| Novo Nordisk | 79 | $1,629 |
| Lilly USA, LLC | 69 | $1,517 |
| Dexcom, Inc. | 56 | $1,305 |
| Bayer | 59 | $1,143 |
| Abbott | 59 | $1,072 |
| AstraZeneca(2 entities) | 26 | $759 |
| Corcept Therapeutics | 24 | $754 |
| Boehringer Ingelheim | 24 | $619 |
| Amarin Pharma, Inc. | 32 | $402 |
| Mannkind Corporation | 11 | $367 |
| Medtronic | 10 | $340 |
| Insulet Corporation | 14 | $313 |
| Sanofi-aventis U.S. LLC | 16 | $258 |
| Xeris Pharmaceuticals, Inc. | 7 | $151 |
| Tandem Diabetes Care, Inc. | 5 | $99 |
| Esperion Therapeutics, Inc. | 4 | $82 |
| Novartis | 4 | $72 |
| Merck | 3 | $71 |
| Radius Health, Inc. | 3 | $71 |
| Chiesi USA, Inc. | 2 | $49 |
| Neurocrine Biosciences, Inc. | 1 | $32 |
| AbbVie | 1 | $27 |
| Lundbeck LLC | 1 | $27 |
| Kyowa Kirin, Inc. | 1 | $26 |
| Kowa Pharmaceuticals America, Inc. | 1 | $17 |
| LEO Pharma Inc. | 1 | $17 |
| Acerus Pharmaceuticals Corporation | 1 | $15 |
| Johnson & Johnson | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MOUNJARO$235
- FARXIGA$232
- Korlym$230
- MINIMED 780G$164
- EVENITY$150
- DEXCOM G7 GSS (161)$135
- DEXCOM STELO GLUCOSE BIOSENSOR$135
- RYBELSUS$125
- Prolia$122
- Wegovy$122
- Kerendia$121
- FREESTYLE LIBRE 3$116
- JARDIANCE$111
- DEXCOM G6 TRANSMITTER$109
How this compares
$13,046 in reported general payments places this provider in the 85th percentile of 22 endocrinology, diabetes & metabolism providers in Hawaii.
See all endocrinology, diabetes & metabolism providers in Hawaii →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 408 | $560,521 |
| JardianceEmpagliflozin | 164 | $228,604 |
| TrulicityDulaglutide | 130 | $213,705 |
| MounjaroTirzepatide | 121 | $208,679 |
| FarxigaDapagliflozin Propanediol | 175 | $206,634 |
| RybelsusSemaglutide | 49 | $88,484 |
| KerendiaFinerenone | 64 | $88,274 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 39 | $45,282 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 52 | $44,657 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 22 | $33,844 |
| ProliaDenosumab | 15 | $26,761 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 47 | $23,232 |
| TradjentaLinagliptin | 21 | $22,368 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 13 | $22,257 |
| JanuviaSitagliptin Phosphate | 15 | $22,205 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog | $1,629 | $653,462475 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Humalog | $1,517 | $429,442273 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Tradjenta | $619 | $284,816207 claims |
| AstraZenecaFarxiga | $759 | $206,634175 claims |
| BayerKerendia | $1,143 | $88,27464 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $258 | $44,65752 claims |
| AmgenProlia | $1,803 | $26,76115 claims |
| MerckJanuvia | $71 | $22,20515 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 22 endocrinology, diabetes & metabolism providers in Hawaii.
Other endocrinology, diabetes & metabolism in Honolulu
- Alan ParsaHonolulu$584K
- Cindy PauHonolulu$13K
- Lisa WongHonolulu$12K
- Eric LeeHonolulu$3K
- Isabel CasimiroHonolulu$2K
- Se Mo SuhHonolulu$2K
- Chanhaeng RheeHonolulu$2K
- Kamonkiat WirunsawanyaHonolulu$1K
- Jennifer LohHonolulu$890
- Lara WongHonolulu$399
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.